Continuous glucose monitors (CGM) continues to advance, with sensors becoming easier to apply, getting longer wear times and better accuracy. The next wave of updates could bring even bigger shifts, including integrations with wearable tech, dual-analyte sensors, and even more AID integrations. Here are five CGM developments worth keeping an eye on.

Dexcom received FDA clearance in April 2025 for its longest-lasting sensor yet, the 15-day G7. Approved for adults 18 and older, it offers up to 15.5 days of wear when the 12-hour grace period is included. This is a significant increase from the current 10-day model. Dexcom says the longer-lasting sensor comes with an upgraded algorithm which improves the accuracy down from a 8.2% MARD to 8.0% MARD (the lower the better). Only time will tell how much of an improvement this is as we’ve discussed on the podcast, MARD can be misleading because there is no universal way to measure it.

In a study run by Dexcom, it found 73.9% of sensors reached the full 15 days, leaving over a quarter that did not. With many insurance plans covering only a one-month supply, even one early failure could leave users short. Dexcom will replace confirmed failures and an additional three goodwill replacements per year. The idea of fewer insertions and less applicators to pack makes the 15-day G7 an exciting advancement — one I’m looking forward to using myself. The updated sensor is expected to launch by the end of 2025.

Dexcom Stelo is an over-the-counter biosensor (aka CGM) designed for adults who do not use insulin, including people with prediabetes, type 2 diabetes, or even those without diabetes who want to track lifestyle impacts on glucose. Stelo now integrates with the Oura Ring, allowing users to see glucose alongside sleep, activity, meals, and recovery metrics inside the Oura app.

Two features stand out: Meals, which lets users log or edit food inputs, and Glucose, which displays meals and lifestyle factors alongside glucose response on in-app graph. In our interview with Dexcom, COO Jake Leach told us the long-term goal is to offer personalized habit recommendations and eventually extend similar insights to G7 users. Over time, this could potentially influence insulin delivery by showing how various behaviors affects glucose levels.

Abbott is developing a sensor that measures both glucose and ketones. Ketones could be an important metric for people with diabetes to prevent diabetic ketoacidosis (DKA) which results from a build up of ketones. With the use of certain drugs, it’s possible to have a rise in ketones without a noticeable change in glucose levels — this sensor could alert users ahead of an issue. Currently, ketone monitoring relies on urine strips or fingersticks—methods that are easy to skip (I’m guilty of not testing ketones ever in my four years of T1D). A dual-analyte sensor could provide continuous tracking and early warning before ketones reach dangerous levels.

The sensor is still in development and hasn’t received FDA clearance yet, but Abbott already has pump partners for the sensor to integrate it with insulin pumps.

Medtronic is doubling down in the CGM market with two (well, three) new sensors. First is Simplera, a fully disposable 7-day CGM already available in many countries outside the US. It’s designed to work with the InPen smart insulin pen to power its smart MDI system. Then there’s Simplera Sync, which has the same build, but connects directly with the MiniMed 780G pump. Production delays have slowed Simplera rollout, but rollout in the US is expected in the Fall of 2025.

The second sensor, Instinct, is being developed with Abbott. From public images, it appears to look similar to the Libre 3 Plus, but it will be proprietary to Medtronic systems and function only within its ecosystem. The CGM will have a 15 day weartime and likely function similar to Libre 3 Plus. Together, Simplera, Simplera Sync, and Instinct demonstrate Medtronic’s effort to catch up in a competitive CGM market while offering both disposable and integrated options for different user needs.

Eversense remains the only implantable CGM on the market, with a sensor placed under the skin of the upper arm via a short procedure. A lightweight, removable and rechargeable transmitter is worn externally. The Eversense 365 took a major step forward, with a sensor designed to last a full year — meaning only one insertion is needed annually. It requires a weekly calibration, it has on-body vibration alerts, and its rechargeable transmitter can be taken on and off throughout the day (although readings won’t record for periods it is removed).

Senseonics executives have confirmed work on a future version that would remove the need for an external transmitter, creating an even more streamlined CGM system. Integration with the upcoming Twiist AID system means Eversense 365 will help provide automated insulin delivery for the first time. Eversense 365 will become the only long-term, implantable CGM that offers continuous automated insulin alongside a pump..

CGM tech is evolving fast, and we’re here to help you stay ahead. Subscribe to our free newsletter to stay on top of the latest diabetes tech announcements and check out the video below to learn more about these CGM upgrades in greater detail.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.